Amgen’s Imlygic Approval A Milestone For Oncolytic Cancer Vaccines
This article was originally published in The Pink Sheet Daily
Executive Summary
Company prices Imlygic (T-VEC) cancer vaccine at the average cost of $65,000, aims to launch within a week.